<DOC>
	<DOCNO>NCT01929109</DOCNO>
	<brief_summary>The purpose study measure much study drug , LY2409021 , get blood stream long take body get rid give participant different level kidney function . There five study group . Each participant may enroll one group . Participants group 1 4 may healthy may mild , moderate , severe kidney disease . They complete one study period last 29 day . Study group 5 enroll participant kidney disease dialysis . They complete two study period together last 59 day . Screening require within 21 day prior start study participant .</brief_summary>
	<brief_title>A Study LY2409021 Participants With Different Levels Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Inclusion Criteria ALL Participants Male participant must agree use reliable method birth control addition partner use another method duration study 3 month last dose LY2409021 Female participant must childbearing potential Participants body mass index ( BMI ) 18 40 kilogram per meter square ( kg/m^2 ) , inclusive , screen Additional Inclusion Criteria Control ( Healthy ) Participants Control participant must normal renal function , assess mean estimate creatinine clearance ( CLcr ) great equal ( â‰¥ ) 90 milliliter per minute ( mL/min ) screen day dose Additional Inclusion Criteria Participants MildtoSevere Renal Impairment End Stage Renal Disease ( ESRD ) Males females stable mildtosevere renal impairment , assess estimate CLcr , ESRD require hemodialysis ( hemodiafiltration ) least 3 month Additional Inclusion Criteria Participants Type 2 Diabetes Mellitus ( T2DM ) Participants T2DM treat diet exercise alone receive treatment insulin Exclusion Criteria ALL Participants Participants require peritoneal dialysis Participants current , functioning , organ transplant Participants show evidence significant active uncontrolled endocrine autoimmune abnormality ( example , thyroid disease , pernicious anemia ) judge screen physician Participants febrile illness within 3 day prior screen Participants abnormality 12lead Electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study . [ Participants QT interval correct use Fridericia 's ( QTcF ) formula &gt; 450 millisecond ( msec ) PR interval &gt; 0.22 sec screen ECG , risk factor Torsades de Pointes ] Participants show evidence significant active neuropsychiatric disease Participants currently use intend use potent inhibitor cytochrome P450 ( CYP ) 3A , include limited atazanavir , indinavir , nelfinavir , ritonavir , clarithromycin , itraconazole , ketoconazole , nefazodone , saquinavir , telithromycin Participants currently use drug narrow therapeutic index ( example , digoxin , lithium , phenytoin , theophylline , warfarin ) Participants currently use drug know prolong QT interval Additional Exclusion Criteria Participants Mild , Moderate Severe Renal Impairment ESRD : Participants use drug indicate medical care participant 's renal impairment , establish dose administer least 7 day LY2409021 administration Participants poorly control hypertension ( systolic blood pressure ( BP ) less ( &gt; ) 160 , diastolic BP &gt; 95 mm Hg ) and/or evidence labile blood pressure include symptomatic postural hypotension Participants hemoglobin &lt; 9 gram per deciliter ( g/dL ) significant active hematologic disease cause underlying renal disease Additional Exclusion Criteria Participants T2DM : Participants use oral injectable antihyperglycemic agent , except insulin , within 1 month prior dose ( Day 1 ) Participants experience ketoacidotic episode ( pH &lt; 7.3 ) require hospitalization last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>